The health tech company Digital Diagnostics AG from Mainz, Germany, has received approval for clinical trials from a German ethics committee and the Federal Institute for Drugs and Medical Devices (BfArM). This is a crucial regulatory step in the ongoing approval process for the Digid Cantisense™ SARS-CoV-2 test in Germany. The aim of the clinical trials is to demonstrate the reliability of the new technology in comparison with conventional PCR tests. The new test is particularly suitable for access control at airports or at large-scale event
Read MoreTo help prevent the spread of COVID-19 in Houston, Texas, Baylor Genetics has partnered with the Houston Health Department, City of Houston (COH), to provide quality, high-throughput testing for COVID-19
Read MoreAt the Helmholtz Centre for Infection Research (HZI), scientists have succeeded for the first time in detecting SARS-CoV-2 viruses using the revolutionary Cantisense™ technology from Digital Diagnostics AG. Application for approval of the Digid Cantisense™ SARS-CoV-2 Test by the FDA has been submitted. Delivery of the first point-of-care tests is planned for July.
Read MoreA new type of sensor device from the German health technology company Digital Diagnostics AG can be used for immediate tests for the new SARS coronavirus. In comparison to currently available rapid tests, the SARS-CoV-2 MEMS 5 Minute Test™ directly detects the virus over the entire course of the infection and can be read immediately, without the need for a laboratory.
Read MoreARTIDIS AG ("ARTIDIS"), a privately held healthtech company, announced today the successful closure of a CHF 8.8 million seed financing in two rounds, securing early clinical validation and the next development phase towards market entry in 2021.
Read MoreARTIDIS announces its successful integration in the highly competitive international Medical Device Cohort 2019 of the Texas Medical Center's (TMC) Innovation Institute.
Read MoreHands-On Diagnostics completed its 5th Annual Symposium with the announcement of the winners of the Practice of the Year Awards aimed to honor Physical Therapists for their contributions to their communities and to the profession of Physical Therapy.
Read MoreThe 4th Annual Symposium of Hands-On Diagnostics gives the opportunity to Physical Therapists to discuss the future of the Physical Therapy profession with use of advanced diagnostic technologies.
Read MoreHands-On Diagnostics expands its reach to the Western US with the establishment of a new consortium dedicated to physical therapists from the Western US States; the new training program starts in July 2017
Read MoreRam Group Aims to Introduce Revolutionary Low-Cost Point-of-Care Diagnostics and Healthcare Monitoring Devices to Low-Income Communities.
Read MoreHands-On Diagnostics' developing residency program in clinical electrophysiology for the performance of electrodiagnosis has been granted recognition status by the AMERICAN BOARD OF PHYSICAL THERAPY RESIDENCY & FELLOWSHIP EDUCATION (ABPTRFE).
Read Moremiacom diagnostics GmbH, Duesseldorf, a company focused on the development and production of medical tests for the detection of acute infectious diseases, today announced the U.S. Food and Drug Administration (FDA) clearance.
Read MoreA clinical trial involving Janssen Diagnostics' CELLSEARCH® System has been recognized by the editors of Clinical Cancer Research1 as being among the most significant studies to appear in the journal in its 20 year history.
Read MoreCreodyne, LLC, announced today filing a US patent application entitled, "Autonomous Self-Assembling DNA Nanodevice for Molecular Interrogation, Detection, Energetics, and Force Measurement" (Application No. 62/120,308). The invention and technology constitute a new paradigm for interrogating interactions between and within molecules.
Read More